During our recent Phacilitate Advanced Therapies Week breakfast briefing, cell therapy manufacturing executives Nicholas Ostrout from Lonza, Fabio Fachin from Takeda and Matthew Li from Vor Biopharma shared their insights on disruptive technologies in cell therapy. Invetech’s David Hodl, Head of Business Development, moderated the discussion.

Introducing new technologies into a cell therapy manufacturing process presents multiple potential benefits, risks and cost. Understanding the critical decisions points that companies face as they scale their production and move towards commercialization can help manufacturers introduce disruptive technologies appropriately.

The panel discussed: 

  • Evaluation criteria for bringing in new manufacturing technology
  • The factors involved in aligning platform and process development
  • Bringing disruptive technologies into the process in the context of clinical timelines
  • When is it beneficial to use something in PD (process development) before it is GMP (good manufacturing practice) ready?


Fabio Fachin, Head Cell Therapy Process Development, Automation and Digital Technologies, Takeda

Matthew Li, Associate Director, Head of Cell Therapy Manufacturing Innovation, Vor Biopharma

Nicholas Ostrout, Senior Director Commercial Strategy and Implementation, Lonza

For a deeper dive into developing a manufacturing roadmap as well as how to prioritize automation processes, reduce time to commercialization and more, explore our Guide to Transitioning Clinical Cell Therapy Manufacturing to Commercial Scale.

Guide to Transitioning Clinical Cell Therapy Manufacturing to Commercial Scale

How to find the right automation inflection point, prioritize automation processes and reduce time to commercialization.